Silmitasertib (sodium salt) (Standard)

Silmitasertib (sodium salt) (Standard) is the analytical standard of Silmitasertib (sodium salt) . This product is intended for research and analytical applications. Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.

Product Specifications

CAS Number

[1309357-15-0]

UNSPSC

12352100

Target

Autophagy; Casein Kinase; Reference Standards

Related Pathways

Autophagy; Cell Cycle/DNA Damage; Others; Stem Cell/Wnt

Field of Research

Cancer

Smiles

O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)O[Na]

Molecular Formula

C19H11ClN3NaO2

Molecular Weight

371.75

References & Citations

[1]Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70 (24) :10288-98.|[2]Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7 (2) :1323-40.|[3]Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.|[4]Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7 (33) :53191-53203.